Compare Cassava Sciences Inc (FLNA) vs Matson Inc (MATX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Matson Inc — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Matson Inc trades at $227.59 (market cap $6.32B). The key difference: Matson Inc is far larger — about 118.9× Cassava Sciences Inc's market cap, and Matson Inc pays a 0.73% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | MATX | |
|---|---|---|
Market Cap | $53.14M | $6.32B |
Sector | Health | Technology |
52-Week High | $4.64 | $210.95 |
52-Week Low | $1.09 | $88.05 |
Enterprise Value | -$33.43M | $6.92B |
Dividend Yield | — | 0.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Matson (MATX) trades at $223.32, up 5.86% today, showing strong momentum. The stock is technically bullish with moving averages aligned positively, though oscillators signal some near-term caution. Fundamentally, the company maintains solid profitability with a 12.92% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights preliminary Q2 results expecting higher operating income and a dividend increase to $0.38 per share.
The outlook for MATX is positive, supported by earnings beats, dividend growth, and strategic fleet renewal. Key opportunities include its niche Pacific shipping routes and e-commerce demand. Risks involve exposure to global trade volatility and potential margin pressure from operational costs. Analyst consensus is bullish with 64% buy ratings, but investors should monitor quarterly earnings execution amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →
